Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population

References

• Jacobsen BA, Fallingborg J, Rasmussen HH, Nielsen KR, Drewes AM, Puho E, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol 2006; 18: 601–6
   PubMed Web of Science ®Google Scholar
• Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003; 37: 358–67
   PubMed Web of Science ®Google Scholar
• Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis 2004; 10: 300–11
   PubMed Web of Science ®Google Scholar
• Ernst A, Jacobsen B, Ostergaard M, Okkels H, Andersen V, Dagiliene E, et al. Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. Scand J Gastroenterol 2007; 42: 1–7
   Google Scholar
• Pena AS. Contribution of genetics to a new vision in the understanding of inflammatory bowel disease. World J Gastroenterol 2006; 12: 4784–7
   PubMedGoogle Scholar
• Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949–58
   PubMed Web of Science ®Google Scholar
• Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005; 70: 695–9
   PubMed Web of Science ®Google Scholar
• Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733–44
   PubMed Web of Science ®Google Scholar
• Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26–40
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 2006; 58: 720–8
   PubMed Web of Science ®Google Scholar
• Larsen UL, Hyldahl OL, Guldborg NC, Eriksen J, Jakobsen P, Ostergaard M, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007; 67: 123–34
   PubMed Web of Science ®Google Scholar
• Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004; 311: 1179–87
   PubMed Web of Science ®Google Scholar
• Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12: 3636–44
   PubMed Web of Science ®Google Scholar
• Zubor P, Lasabova Z, Hatok J, Stanclova A, Danko J. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 2007; 18: 211–7
   PubMed Web of Science ®Google Scholar
• Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet 2006; 15: 797–805
   PubMed Web of Science ®Google Scholar
• Urcelay E, Mendoza JL, Martin MC, Mas A, Martinez A, Taxonera C, et al. MDR1 gene: susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflamm Bowel Dis 2006; 12: 33–7
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, et al. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 516–23
   PubMed Web of Science ®Google Scholar
• Backstrom G, Taipalensuu J, Melhus H, Brandstrom H, Svensson AC, Artursson P, et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003; 18: 359–64
   PubMed Web of Science ®Google Scholar
• Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004; 20(109)238–46
   Google Scholar
• Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611–6
   PubMed Web of Science ®Google Scholar
• Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004; 21: 1895–903
   PubMed Web of Science ®Google Scholar
• Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003; 13: 19–28
   PubMedGoogle Scholar
• Fischer S, Lakatos PL, Lakatos L, Kovacs A, Molnar T, Altorjay, , et al. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases. Scand J Gastroenterol 2007;42:726–33.
   PubMed Web of Science ®Google Scholar
• Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Scientific World J 2006; 6: 577–88
   Google Scholar
• Morteau O, Morham SG, Sellon R, Dieleman LA, Langenbach R, Smithies O, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105: 469–78
   PubMedGoogle Scholar
• Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076–85
   PubMed Web of Science ®Google Scholar
• Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565–76
   PubMed Web of Science ®Google Scholar
• Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004; 114: 248–53
   PubMed Web of Science ®Google Scholar
• Sanak M, Szczeklik W, Szczeklik A. Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol 2005; 116: 221–3
   PubMedGoogle Scholar
• Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, Canzian F. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J Gastroenterol 2005; 11: 6003–8
   PubMedGoogle Scholar
• Sansbury LB, Millikan RC, Schroeder JC, North KE, Moorman PG, Keku TO, et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006; 17: 257–66
   PubMedGoogle Scholar
• Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 616–9
   PubMedGoogle Scholar
• Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC. Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004; 25: 2467–72
   PubMedGoogle Scholar
• Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462–71
   PubMed Web of Science ®Google Scholar
• Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 2005; 112: 941–5
   PubMedGoogle Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417–29
   PubMed Web of Science ®Google Scholar
• Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631–6
   PubMed Web of Science ®Google Scholar
• Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138–46
   PubMed Web of Science ®Google Scholar
• Rajakariar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv 2006; 6: 199–207
   PubMedGoogle Scholar
• Brzozowski T, Konturek PC, Pajdo R, Kwiecien SN, Konturek S, Targosz A, et al. Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 2005; 13: 317–30
   PubMedGoogle Scholar
• Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 103–12
   PubMed Web of Science ®Google Scholar
• Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844–9
   PubMed Web of Science ®Google Scholar
• DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002; 34: 385–96
   PubMed Web of Science ®Google Scholar
• Onnie CM, Fisher SA, Pattni R, Sanderson J, Forbes A, Lewis CM, et al. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis 2006; 12: 263–71
   PubMed Web of Science ®Google Scholar
• Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther 2005; 22: 1129–38
   PubMed Web of Science ®Google Scholar
• Goldstein DB, Hirschhorn JN. In genetic control of disease, does “race” matter?. Nat Genet 2004; 36: 1243–4
   PubMedGoogle Scholar
• McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 2005; 112: 1024–9
   PubMed Web of Science ®Google Scholar
• Guo X, Liu ES, Ko JK, Wong BC, Ye Y, Lam S, et al. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol 2001; 411: 193–203
   PubMed Web of Science ®Google Scholar